Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03831711 · ClinicalTrials.gov registry record · Phase 1
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
A Phase 1 study, sponsored by Andrei Iagaru.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03831711: Completed Phase 1 study, sponsored by Andrei Iagaru.
NCT03831711 is a Phase 1 study that has completed, run by Andrei Iagaru. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03831711, a Phase 1 study, has completed, sponsored by Andrei Iagaru.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.
Primary Outcome
Number of lesions identified on 68-Ga RM2 positron emission tomography/magnetic resonance imaging (PET/MRI). The outcome will be reported as the number of participants with successful PET based detection of estrogen receptor (ER) positive breast cancer and metastases.
Interventions
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography
- DRUG Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
- DEVICE Investigational software and coils in PET/MR scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 1 |
What the finished NCT03831711 record still lists
NCT03831711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT03831711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03831711 about?
NCT03831711 is a clinical study titled "68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer". This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.
What is the current status of trial NCT03831711?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-03-19. Estimated completion is 2021-11-15.
What interventions are being tested in trial NCT03831711?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Gallium Ga 68-labeled GRPR Antagonist BAY86-7548 (DRUG), Investigational software and coils in PET/MR scan (DEVICE).
Who is sponsoring clinical trial NCT03831711?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03831711's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI